Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quince Therapeutics, Inc. - Common Stock (NQ: QNCX )

0.7900 +0.0100 (+1.28%)
Streaming Delayed Price Updated: 12:37 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quince Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
From Quince Therapeutics, Inc.
Via Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024
Quince Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value
Via ACCESSWIRE
Biomed Industries, Inc. Offers to Acquire Quince Therapeutics, Inc.
Via ACCESSWIRE
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023
Quince Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Launches Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Participate at Investor Events in January 2024
From Quince Therapeutics, Inc.
Via Business Wire
SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying
The Dow Jones closed higher by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Over $2M Bet On This Industrial Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
From Quince Therapeutics, Inc.
Via Business Wire
Why Glimpse Group Shares Are Trading Lower By Around 41%; Here Are 20 Stocks Moving Premarket
Gainers RVL Pharmaceuticals plc (NASDAQ: RVLP) shares rose 181.8% to $0.2201 in pre-market trading. 
Via Benzinga
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
From Quince Therapeutics, Inc.
Via Business Wire
What's Going On With Quince Therapeutics Stock Today
Quince Therapeutics Inc (NASDAQ: QNCX) has agreed to acquire EryDel SpA, a privately-held, late-stage biotech company, in a stock-for-stock upfront exchange and potential downstream  
Via Benzinga
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
From Quince Therapeutics, Inc.
Via Business Wire
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.
Via ACCESSWIRE
Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital
From Quince Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.